Vendor Intelligence Report: Peptidology
Published 12 Nov 2026. 37-page investigative report on who is behind Peptidology: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 5 pages are free to read on this page.
Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.
Executive summary
Across 25 Finnrick lab tests, Peptidology’s overall record is 21 pass / 4 fail, an 84% pass rate. The useful read is product-specific rather than blanket. GHK-Cu and PT-141 are the cleanest signals in the current record, while BPC-157 is the clear weak point and Ipamorelin remains conditional. The full product appendix shows how several ratings move when stricter grading is applied.
The public operating footprint is unusually document-heavy for this market: a Scottsdale-facing storefront, a disclosed Arizona contracting entity, named outside labs, a large COA library and a public testing page. That transparency has limits. The same testing page presents perfect-looking sterility and germ counters beside a held-back-batch disclosure and named failures, leaving the denominator unresolved rather than independently auditable.
Corporate and trademark records support Nine of One LLC as the retail entity and Joshua Strickland as the founder-linked principal, but the exact membership schedule was not public. Supply-chain visibility is weaker: Peptidology describes U.S. and Taiwan contract manufacturing and API sourcing without naming facilities, suppliers, audits or facility-level certificates. The GLP-1 storefront pages add a separate buyer problem by using coded labels where the molecule identity must be reconciled through COAs.
The investigation also maps promotion and continuity risks that do not show up in lab statistics: a same-brand review site with affiliate routing, founder-linked adjacent ventures, channel-confusion issues, a deleted Reddit account, and current checkout restrictions affecting major card rails. None of those points proves product substitution or a supply interruption; they do affect how much independent verification a buyer should require before ordering.
Inside the full report:
- Per-product pass/fail rates, rating trajectories and methodology-divergence charts for all 9 tested products.
- Corporate, trademark and address records linking Peptidology to Nine of One LLC and the Scottsdale operating footprint.
- Sterility-denominator analysis comparing public pass counters with held-back batches and named failures.
- COA and lab review covering Vanguard, Eagle Analytical, Ethos Analytics and the BPC-157 lot-document example.
- Affiliate-flow and founder-network mapping across Peptidology.io, BestPeptideStores, Peptide Startups and RUO Partners.
- Buyer guidance by product, including BPC-157, Ipamorelin, GLP-1 identity checks and payment-recourse considerations.
Risk assessment
- BPC-157 product-quality risk — high: Finnrick records BPC-157 at 3 tests, 0 pass, 3 fail, 45.7% rating; a passing lot 1727 COA does not establish that Finnrick's failed samples came from that lot.
- Ipamorelin product-quality variability — medium: Finnrick records Ipamorelin at 3 tests, 2 pass, 1 fail, 67.15% rating; treat current lot verification as mandatory.
- Sterility/batch-release disclosure inconsistency — high: The Testing page claims 261/261 germ passes and 257/257 sterility passes while also reporting 12 held-back batches, 2 mixed-vial batches and 3 named failed batches.
- Affiliate/undisclosed-promotion conflict — high: Peptidology.io shares the brand, ranks Optides #1 and redirects with ref=PEPTIDOLOGY while not disclosing common brand/control with the retail store.
- Coded GLP-1 product-identity risk — medium: PGL-G1, PGL-GI1 and PGL-GIC1 omit molecular names on product pages; likely semaglutide/tirzepatide/retatrutide mapping requires COA and lot verification.
- Supplier/manufacturing opacity risk — medium: Finished-product manufacturers in the U.S. and Taiwan and API suppliers are unnamed; cGMP-aligned is not a facility certificate or public audit trail.
- Brand-confusion/channel-verification risk — medium: The canonical store is peptidology.co, but same-brand peptidology.io, @officialpeptidology, subreddit bookmarks and coupon sites exist without a clear official-channels or authorized-reseller list.
- Payment-rail stress — medium: Checkout blocks Mastercard and Discover while offering Visa/Amex/Apple Pay/bank/Zelle; this is a recourse and continuity concern, not proof of a MATCH/TMF listing.
- Founder-network conflict concentration — medium: The founder is linked to Peptidology, Peptide Startups and RUO Partners; no public client list, firewall or cross-ownership disclosure was found.
- Adverse-event process gap — medium: The Terms provide general contact and dispute language but no structured adverse-event intake for lot, symptoms, timing, storage, route and outcome.